Curcumin inhibits hepatitis C virus replication via suppressing the Akt-SREBP-1 pathway  by Kim, KyeongJin et al.
FEBS Letters 584 (2010) 707–712journal homepage: www.FEBSLetters .orgCurcumin inhibits hepatitis C virus replication via suppressing
the Akt-SREBP-1 pathway
KyeongJin Kim a, Kook Hwan Kim a, Hye Young Kim a, Hyun Kook Cho a, Naoya Sakamoto b, JaeHun Cheong a,*
aDepartment of Molecular Biology, College of Natural Sciences, Pusan National University, Busan 609-735, Republic of Korea
bDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo 113-8519, Japana r t i c l e i n f o
Article history:
Received 20 October 2009
Revised 3 December 2009
Accepted 12 December 2009
Available online 17 December 2009
Edited by Lukas Huber
Keywords:
Akt
Curcumin
HCV
NS5A
SREBP-10014-5793/$36.00  2009 Federation of European Bio
doi:10.1016/j.febslet.2009.12.019
* Corresponding author. Fax: +82 51 513 9258.
E-mail addresses: molecule85@pusan.ac.kr, jhcheoa b s t r a c t
A polyphenolic compound from the curry spice turmeric, curcumin, is known to show anti-viral
activity against the inﬂuenza virus, adenovirus, coxsackievirus, and the human immunodeﬁciency
virus. However, it remains to be determined whether curcumin can inhibit the replication of hepa-
titis C virus (HCV). In this study, we showed that curcumin decreases HCV gene expression via sup-
pression of the Akt-SREBP-1 activation, not by NF-jB pathway. The combination of curcumin and
IFNa exerted profound inhibitory effects on HCV replication. Collectively, our results indicate that
curcumin can suppress HCV replication in vitro and may be potentially useful as novel anti-HCV
reagents.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The hepatitis C virus (HCV), a member of the Flaviviridae family,
is an enveloped virus with a single-stranded 9.6 kb RNA genome.
HCV infection is characterized by a high rate of progression to
ﬁbrosis and chronic hepatitis, resulting in cirrhosis, and ultimately
in hepatocellular carcinoma [1]. The best anti-viral therapy pres-
ently known involves the combination of pegylated interferon
(IFN) alpha and ribavirin, but almost half of all patients manifest
no response to exogenous IFNa [2]. Therefore, the development
of novel drugs for the safer and more efﬁcient treatment of HCV
is urgently required.
Many bioactive polyphenolic compounds have been shown to
perform candidate agent functions in chemoprevention and in can-
cer chemotherapy [3]. Among this class, curcumin (diferuloylme-
thane) is one of the most widely studied compounds. Curcumin
is the major component of the curry spice tumeric (Curcuma longa
Linn) and can affect the metabolism of cells and organisms in a
number of ways, including anti-inﬂammatory, anti-oxidant, and
anti-proliferative properties via the modulation of multiple cellular
mechanisms [4,5]. Furthermore, some recent reports have shown
that these compounds show anti-viral activity against the inﬂu-
enza virus, adenovirus, coxsackievirus, and the human immunode-
ﬁciency virus [6–9]. Also, curcumin has been shown to suppresschemical Societies. Published by E
ng2@lycos.co.kr (J. Cheong).transcription activation by the host protein AP-1, leading to dimin-
ished HTLV-1 and HPV-mediated cellular transformation [10].
However, it remains to be determined whether curcumin can inhi-
bit the gene expression of HCV.
On the basis of our previous knowledge of the regulation of HCV
replication and the biological properties of curcumin, we evaluated
the effects of curcumin on the intracellular replication of the HCV
genome in vitro, using an HCV replicon system. We showed that
curcumin at concentrations that do not affect cell viability reduced
HCV RNA replication in vitro to a signiﬁcant degree. Curcumin
inhibited a lipogenic transcription factor, sterol regulatory element
binding protein-1 (SREBP-1)-induced HCV replication via the PI3K/
Akt pathway. Finally, the combination of curcumin and IFNa
showed cooperative inhibitory effects on HCV RNA replication.
Our results indicate that curcumin may potentially prove useful
as a treatment for HCV infection.2. Materials and methods
2.1. Plasmid constructs
pEMCV/IRES-Rluc was utilized as a control for the analysis of
translation efﬁciency mediated by an encephalomyocarditis virus
internal ribosome entry site (EMCV-IRES) which mediates the
translation of the HCV non-structure gene of replicon constructs,
Huh7/Rep-Feo [11]. pCIneo-Rluc-IRES-Fluc was constructed inlsevier B.V. All rights reserved.
708 K. Kim et al. / FEBS Letters 584 (2010) 707–712order to evaluate HCV internal ribosome entry site (IRES)-mediated
translation efﬁciency [12]. The plasmid expressed a bicistronic
RNA, in which Rluc was translated in a cap-dependent manner
and Fluc was translated via HCV IRES-mediated initiation.
2.2. Cell cultures and treatments
Huh7 cells expressing the HCV replicon (Huh7/Rep-Feo) were
maintained in DMEM supplemented with 10% FBS containing
500 lg/ml of G418 (Calbiochem). Huh7/Rep-Feo and Huh7 cells
were plated at 70–80% conﬂuence and treated with various con-
centrations of curcumin or vehicle controls and incubated for
24 h at 37 C. The concentration ranges of 5–15 mM curcumin (ob-
tained from Sigma) were tested. Control vehicle treatment (DMSO)
was equivalent to the highest concentrations in the dose range
experiments for each of the tested drugs.
2.3. HCV replicons
An HCV subgenomic replicon plasmid, pRep-Feo (Fig. 1A), was
derived from pRep-Neo (originally referred to as pHCVIbneo-delS)
[13]. Replicon RNA was synthesized in vitro using T7-RNA poly-
merase (Promega, Madison, WI) and transfected into the Huh7
cells via electroporation. After culturing in the presence of G418,
the cell lines stably expressing the replicons were established
and designated Huh7/Rep-Feo.
2.4. Transient transfection and luciferase reporter assay
Plasmid transfection was conducted using PolyFect (QIAGEN) in
accordance with the manufacturer’s instructions. The pcDNA3.1
empty vector was added to the transfections in order to achieve
the same total amount of plasmid DNA per transfection. The cells
were lysed in cell culture lysis buffer (Promega). The luciferase
activity was evaluated using an analytical luminescence lumino-
meter in accordance with the manufacturer’s instructions.0
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Fig. 1. Curcumin suppresses HCV RNA replication. (A) Structures of the hepatitis C vir
effects of curcumin on Huh7/Rep-Feo cells on luciferase activity and MTT assays. For
indicated curcumin concentrations, and the luciferase activity was determined at 24
independent experiments. *P < 0.05 compared with control. (C) The luciferase activity
curcumin. The data are expressed as the means ± S.D. (n = 3). (D) The inhibitory effect of H
the presence of 15 lM curcumin. Total RNA was extracted from the cells, and the levels o
as an mRNA-loading control. Total protein extracts were blotted with anti-NS5A antibo
experiments were reproduced.2.5. MTT assay
For cell viability assay, Huh7/Rep-Feo cells were seeded in a 24-
well tissue culture plate and incubated for 24 h. Cells were treated
with curcumin or Bay11-7082. After 24 h, MTT (3-(4,5-dimethyl-
thiozol-2-ly)-2,5-diphenyltetrazolium bromide) solution (0.5 mg/
ml) was added to each well. After incubation for 2 h at 37 C, for-
mazan crystals in viable cells were soluble in 200 ll of DMSO.
The soluble formazan product was spectrophotometrically quanti-
ﬁed using an ELISA leader at 570 nm.2.6. siRNA design and siRNA transfection
RNA oligonucleotides were synthesized by Bioneer (Daejeon,
Republic of Korea). The sequences of siRNA targeting human p65
were sense, 50-GAU UGA GGA GAA ACG UAA A-30 and antisense,
50-UUU ACG UUU CUC CUC AAU C-30. The sequence of siRNA target-
ing human SREBP-1 were sense, 50-UGA GUG GCG GAA CCA UCU U-
30 and antisense, 50-AAG AUG GUU CCG CCA CUC A-30. The scram-
ble control siRNA sequences were sense, 50-CCU ACG CCA CCA AUU
UCG U-30 and antisense, 50-ACG AAA UUG GUG GCG UAG G-30. The
cells were transfected with siRNA using HiPerFect (QIAGEN)
according to the instructions of the manufacturer.2.7. RT-PCR analysis
Total RNA from the curcumin-treated Huh7/Feo cells was pre-
pared using TRIzol reagent (Invitrogen) by following the manufac-
turer’s instructions. cDNA was used as a template for real-time PCR
using gene-speciﬁc primers: NS3, 50-TCG TGG CAA CAG ACG CTC
TAA TGA-30 (forward) and 50-AGA ACT CCA G AT GGT CCT GGC
AAA-30 (reverse); NS5A, 50-TAG CAG TGC TCA CTT CCA TGC TCA-
30 (forward) and 50-AGG ATC TCC GCC GCA ATG GAT ATT-30 (re-
verse); b-actin, 50-GAC TAC CTC ATG AAG ATC-30 (forward), 50-
GAT CCA CAT CTG CTG GAA-30 (reverse).luc-IRES-Fluc pEMCV/IRES-Rluc
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Cells were lysed in buffer A (10 mM HEPES, pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 1 mM DTT, 0.5% NP-40, 1 mM PMSF, protease
inhibitors) and incubated for 10 min on ice. The supernatants
(cytosolic lysates) were collected by centrifugation (3300g) at
4 C for 5 min. The nuclear pellets were then washed with ice-cold
PBS to avoid contamination of cytosolic proteins and lysed in buf-
fer B (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 25% glyc-
erol, 420 mM NaCl, 0.2 mM EDTA, 1 mM DTT, 0.5% NP-40, 1 mM
PMSF, protease inhibitors). After incubation on ice for 25 min, the
supernatants (nuclear lysates) were collected by centrifugation
(13 000g) at 4 C for 5 min.
2.9. Statistical analysis
Statistical analyses were carried out by unpaired or paired t test
as appropriate. All data are reported as means ± S.D. P value of
<0.05 was considered signiﬁcant.
3. Results
3.1. Curcumin suppresses HCV RNA replication
In order to evaluate the effects of curcumin on the intracellular
replication of the HCV genome, Huh7/Rep-Feo cells were treated
with various concentrations of curcumin. The luciferase activity0
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Fig. 2. Curcumin suppressed HCV replication via the PI3 K/Akt pathway. (A) The effects
plates and transfected with scramble control siRNA and p65 siRNA and luciferase activitie
Feo cells were seeded in 24-well culture plates and treated with the Bay11-7082. The e
luciferase activity (right) (n = 3). (C) The effects of curcumin on the nuclear localization o
with curcumin (15 lM). The cyto or nuc indicates the cytosolic or nuclear extracts. (D) The
plasmid for Akt (WT) or myr-Akt and cells were treated for 24 h with 15 lM curcumin o
the means ± S.D. for at least three independent experiments. (E and F) The effect of L
pretreated with 25 lM LY294002 for 2 h, and then incubated further in the absence or p
NS3 or NS5A mRNA levels were detected using RT-PCR and protein levels of NS5A wereof the Huh7/Rep-Feo cells demonstrated that the replication of
the HCV replicon was suppressed by curcumin. The MTT assay
showed no effects on cell viability at various concentrations of
these compounds (Fig. 1B). Moreover, the efﬁciency of EMCV-
IRES-mediated translation was not affected by curcumin (Fig. 1C).
These data indicate that the inhibitory effects on HCV replication
exerted by curcumin are not attributable to cytotoxicity or to an
artiﬁcial effect on the EMCV-IRES, which directly translates the
HCV non-structure protein of the replicon. We then attempted to
determine whether these effects of curcumin on the replication
of the HCV replicon are involved in HCV IRES-dependent transla-
tion. We determined that curcumin gives no effects on the activity
of Fireﬂy luciferase in Huh7 cells that were transiently transfected
with the pCIneo-Rluc-IRES-Fluc reporter (Fig. 1C). Taken together,
these results indicate that curcumin suppresses HCV replication
in vitro and that these effects are not involved in cell viability,
EMCV-IRES-mediated translation, or HCV IRES-dependent
translation.
In an effort to conﬁrm these inhibitory effects on the HCV rep-
licon by curcumin, we attempted to determine whether curcumin
affects the HCV RNA and protein level. HCV replicon RNA level was
detected by RT-PCR by using primers speciﬁc to NS3 and NS5A and
protein level was assayed by Western blots with the anti-NS5A
antibody. As shown in Fig. 1D, curcumin-treated cells expressed
lower levels of the HCV replicon RNA as compared with the control
vehicle-treated Huh7/Rep-Feo cells. Also, we showed that curcu-
min decreases the protein level of HCV NS5A, translated from the1 2
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resence of 15 lM curcumin for 24 h. Luciferase activities were measured (n = 3) (E).
detected by Western blotting (n = 2) (F).
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ase activity of Huh7/Rep-Feo cells.
3.2. Curcumin inhibits HCV replication via the PI3K/Ak pathway, not
NF-jB pathway
In an effort to gain insight into the molecular mechanism by
which curcumin suppresses HCV replication, we then analyzed
the signaling pathways involved in curcumin-inhibited HCV repli-
cation. Previously, it was suggested that the activation of the NF-
jB pathway is involved in the increase of HCV replication
[14,15]. To evaluate the involvement of NF-jB pathway on the cur-
cumin-mediated inhibition of HCV replication, p65 (of NF-jB) siR-
NA and Bay11-7082 (a speciﬁc inhibitor of NF-jB pathway) were
exploited. However, in contrast to our expectations, p65 siRNA
and Bay11-7082 had no effect on HCV replication (Fig. 2A and B).
Furthermore, curcumin also had no effect on the nuclear localiza-
tion of p65 (Fig. 2C). These results show that PDTC and curcumin
exert a synergic-inhibitory effect on HCV replication via NF-jB-
independent pathway.
We next explored other potential pathways for HCV replication
by curcumin. Several signaling pathways and transcription factors
including AP-1, mitogen-activated protein kinases (MAPKs), and
cell cycle machinery have been suggested as the targets of curcu-
min. We examined the effect of several pathways on HCV replica-
tion using treatments of speciﬁc kinase inhibitors or transfection of
plasmid for speciﬁc kinases, including ERK, JNK, p38, Akt, and PKA.
Among many signaling pathways, transfection of plasmid for wild
type (WT)-Akt or constitutive active (myr)-Akt signiﬁcantly aug-A
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Fig. 3. SREBP-1 increases the HCV replicon expression via the PI3 K/Akt pathway. (A and
with the plasmid for SREBP-1a or SREBP-1c and luciferase activities were measured (n = 3
siRNA and luciferase activities were measured (n = 2) (B). *P < 0.05 compared with contr
cells were transfected with the plasmid for SREBP-1a (C) or siRNA for SREBP-1 (D). NS3
detected by Western blotting (n = 2). (E and F) The effect of LY294002 on SREBP-1-induce
1a and then incubated further in the absence or presence of 25 lM LY294002 for 24 h.
protein levels were determined using RT-PCR or Western blotting (n = 2) (F).mented the luciferase activities of HCV replicon (Fig. 2D). Also,
LY294002, a speciﬁc inhibitor of the PI3K/Akt pathway, inhibited
curcumin-suppressed activity of HCV replicon (Fig. 2E). To conﬁrm
these effects on the HCV replicon induced by curcumin, we exam-
ined the HCV RNA and protein levels. As shown in Fig. 2F,
LY294002-treated cells restrained the RNA and protein levels of
HCV replicon inhibited by curcumin. Taken together, these results
suggest that curcumin suppresses HCV replicon expression via the
PI3K/Akt pathway.
3.3. SREBP-1 increases the HCV replicon expression via the PI3K/Akt
pathway
To identify the downstream target of the PI3K/Akt pathway on
HCV RNA replication, we tested several transcription factors regu-
lated by the PI3K/Akt pathway. Among them, two SREBP-1 iso-
forms, SREBP-1a and SREBP-1c, induced the luciferase activity of
the Huh7/Rep-Feo cells. Especially, SREBP-1a showed a profound
effect on HCV replication (Fig. 3A). Previously, it has been sug-
gested that the activation of Akt was able to increase the SREBP-
1 gene expression [16]. Also, in an effort to determine whether
SREBP-1 performs a function in HCV RNA replication, we at-
tempted to knockdown SREBP-1 expression using siRNA for
SREBP-1. As shown in Fig. 3B, siRNA/SREBP-1-transfected cells de-
creased the luciferase activity of the Huh7/Rep-Feo cells.
In an effort to conﬁrm these effects on the HCV replicon exerted
by SREBP-1, we attempted to determine whether SREBP-1 affects
the HCV RNA and protein level. As shown in Fig. 3C, SREBP-1a-
transfected cells enhanced the levels of the HCV replicon RNA asRNA/SREBP-1
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Luciferase activities were measured (n = 3) (E) and NS3 or NS5A mRNA and NS5A
K. Kim et al. / FEBS Letters 584 (2010) 707–712 711compared with the control transfected-Huh7/Rep-Feo cells. Also,
we showed that the knockdown of SREBP-1 expression decreases
the RNA and protein level of HCV replicon (Fig. 3D). Furthermore,
SREBP-1a-transfected cells did not induce the HCV RNA replication
in the presence of LY294002 (Fig. 3E and F). Taken together, SREBP-
1 can increase the HCV replication via the PI3 K/Akt pathway.
3.4. Curcumin suppresses the SREBP-1-induced HCV replication
In order to determine whether SREBP-1-increased HCV RNA
replication is inhibited by curcumin, Huh7/Rep-Feo cells were
transfected with the plasmid for SREBP-1a in the absence or pres-
ence of curcumin treatment. As shown in Fig. 4A, the luciferase
activities of Huh7/Rep-Feo cells were inhibited by curcumin in
the SREBP-1a transfection. Also, these effects were conﬁrmed on
the RNA and protein levels of HCV replicon (Fig. 4B).
3.5. Curcumin and IFNa have synergistic inhibitory effects on HCV
replication
Finally, we examined whether curcumin can affect IFNa-based
inhibition of HCV. IFNa has been shown to exert inhibitory effects
on HCV replication. In order to determine whether curcumin could
affect the IFNa-mediated inhibitory effect on HCV replicon, Huh7/0
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NS3 or NS5A mRNA levels or NS5A protein levels were detected using RT-PCR or WesteRep-Feo cells were treated with a combination of IFNa and curcu-
min. As shown in Fig. 5A and B, curcumin signiﬁcantly augmented
the IFNa-mediated inhibition of HCV replication. Thus, these ﬁnd-
ings demonstrate that cotreatment with curcumin was more effec-
tive than treatment with IFNa alone.
4. Discussion
There is abundant evidence indicating that dietary phytochemi-
cals, including epigallocatechin gallate (EGCG), curcumin, resvera-
trol, and genistein, show anti-viral effects in a variety of virus types
[6–9,17,18]. However, it remains to be determined whether dietary
phytochemicals have anti-viral activity in cases of Hepatitis C. It
was reported that curcumin exhibits anti-oxidant activity by
reducing the generation of reactive oxygen species (ROS). Although
it has been known that oxidative stress decreases HCV replication
[19], a recent study showed that ROS is able to increase the repli-
cation of HCV [20]. According to this study, anti-oxidant pyrroli-
dine dithiocarbamate (PDTC) treatment decreased the expression
of HCV RNA in Huh7 cells expressing HCV subgenomic replicons.
In the present study, we observed that PDTC reduces the activity
of HCV luciferase replicons in Huh7/Rep-Feo cells (data not
shown). In addition, curcumin suppressed the HCV replication in
cooperation with PDTC. Although curcumin had no effect on theNS3
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712 K. Kim et al. / FEBS Letters 584 (2010) 707–712gene expression change of anti-oxidant enzymes, such as, Cu/Zn-
superoxide dismutase (Cu/Zn-SOD), Mn-superoxide dismutase
(Mn-SOD) (data not shown), because curcumin exert the function
as anti-oxidant through various pathways, we could not rule out
the possibility that curcumin decreases HCV replication as anti-
oxidant.
Some reports were demonstrated that despite its beneﬁcial, di-
rect anti-tumor actions, curcumin (and potentially other natural
products) may adversely modulate the cellular response to clini-
cally relevant cytokines or cytotoxic activities against a variety of
tumor targets [21,22]. Therefore, curcumin experimentally evalu-
ated has been found to be non-toxic or to have effective doses
far below its toxic doses in the cancer therapy or blood lipid proﬁle
[23,24]. It is necessary to perform experiments to identify the ade-
quate concentrations of curcumin in relation to inhibition of HCV
replication in vivo.
Curcumin is considered to be a potentially important chemo-
preventive agent against a variety of cancers, including liver cancer
[25]. Recently, it has been reported that curcumin inhibits the
development of human hepatocellular carcinoma [26,27]. In this
report, we demonstrated that curcumin inhibits HCV replicon
expression via the PI3K/Akt-SREBP-1 pathway. Taken together
with previous ﬁndings, although hepatocellular carcinoma is the
outcome of complicated processes by various genetic factors and
environmental factors, our current data suggests the possibility
that curcumin may hinder the development of liver cancer via
the inhibition of HCV replication in HCV-induced hepatocellular
carcinoma.Acknowledgments
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